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STEREOTACTIC RADIATION THERAPY WORKSHOP
A Japan Clinical Oncology Group Trial for Stereotactic Body
Radiation Therapy of Non-Small Cell Lung Cancer
Masahiro Hiraoka, MD, PhD,* and Satoshi Ishikura, MD, PhD†
Stereotactic body radiation therapy (SBRT) is a new treat-
ment modality. To confirm the safety and efficacy, the Radi-
ation Therapy Study Group of the Japan Clinical Oncology
Group (JCOG) has started a phase II study of SBRT for stage
IA non-small cell lung cancer (JCOG 0403). This study is
ongoing with a strict quality control and quality assurance
program, and the results will indicate whether a future phase
III trial comparing SBRT with surgery is warranted. In
addition, international collaboration will be critical to estab-
lish the role of SBRT in the treatment of lung cancer.
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Lung cancer is the leading cause of cancer-related death formen and the second for women in Japan. During 2003,
approximately 57,000 patients died of lung and bronchus
cancer,1 and the number is not decreasing. Because of the
application of spiral computed tomography (CT) for lung
cancer screening, the number of patients with early-stage
non-small cell lung cancer (NSCLC) has increased recently.
The number of elderly patients who are not suitable for
surgery has also increased. Although surgery is the accepted
standard of care for stage I NSCLC, conventional radiother-
apy has been applied for these frail patients with inferior
survival compared with surgery.
Stereotactic body radiation therapy (SBRT) is a new
treatment modality based on the same principles and the great
success of stereotactic radiosurgery/radiotherapy for intracra-
nial tumors. The success and high local control with minimal
toxicity have drawn much interest in the application of this
treatment for extracranial regions, and there are several single
institutional retrospective reports.2–8
Although there is no large-scale prospective trial con-
firming the safety and efficacy of SBRT for early-stage
NSCLC, it has been widely used in Japan. Onishi et al. have
reported the results of a multicenter retrospective survey.9
Data from 245 patients from 13 institutions were analyzed.
There was a large variation in the dose schedule used (18-75
Gy in 1-22 fractions), and they used a biologically effective
dose (BED) to account for it. With a median follow-up of 24
months, local recurrence occurred in 8% for BED 100 Gy
and 26% for BED 100 Gy. The 3-year overall survival for
medically operable patients treated with BED 100 Gy was
88%. Onishi et al. claimed that SBRT may achieve equivalent
local control and survival compared with surgery; however,
as in any retrospective study, it has many inherent limitations:
relatively short follow-up with many censored cases, which
leads to the overestimation of local control and survival;
patient selection because SBRT is more often applied at a
higher dose to a peripheral lesion that has favorable outcome
compared with a central lesion; migration between operable
and inoperable because advanced age was considered to be
inoperable, which may lead to Will Rogers phenomenon; and
a limited number of patients in subgroup analyses.
Therefore, we decided to develop a prospective trial
to evaluate the safety and efficacy of SBRT for stage IA
NSCLC.
JAPAN CLINICAL ONCOLOGY GROUP TRIAL OF
SBRT FOR STAGE IA NSCLC
The Japan Clinical Oncology Group (JCOG) 0403 is a
single-arm phase II study. This study was planned to deter-
mine whether SBRT is superior to conventional radiotherapy
for medically inoperable patients and to explore whether
SBRT can achieve survival comparable to that with surgery
for operable patients with clinical stage IA NSCLC. The
primary endpoint is 3-year overall survival, and the planned
accrual was 100 inoperable and 65 operable patients. Local
progression-free survival, patterns of failure, and toxicity
were included as secondary endpoints.
Eligibility criteria included previously untreated pa-
tients with pathologically proven NSCLC; age 20 years;
performance status (based on Eastern Cooperative Oncology
Group scale) 0 to 2; PaO260 torr; and FEV1.0700 ml. All
patients signed written informed consent in accordance with
each institutional review board.
Patients were stratified into two groups after consulta-
tion with an experienced thoracic surgeon: 1) operable pa-
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tients with postoperative predicted FEV1.0 800 ml, PaO2
65 torr, absent severe cardiac/heart disease, and absent
severe diabetes mellitus; 2) inoperable patients who do not
satisfy the criteria for operable patients.
The treatment consists of 48 Gy in four fractions over
4 to 8 days. The prescription point is the isocenter, and the
monitor units are calculated with heterogeneity correction.
The Clarkson integration algorithm is used, and the convo-
lution-superposition algorithm is not allowed in this study.
In treatment planning, the clinical target volume (CTV)
was defined as the gross tumor volume (GTV). An internal
margin according to each institution was added to the CTV to
define the internal target volume (ITV). The planning target
volume (PTV) was defined as the ITV plus 5 mm of setup
margin. The radiation ports were set to the PTV with 5 mm
of leaf margin. Non-coplanar static beams (5 to 10 ports) or
multiple-arc beams (in total 400 degrees) with 4 to 10 MV
X-rays are allowed. Dose constraints to normal tissues, i.e.
the lung, the esophagus, the bronchial tree, the great vessels,
the spinal cord, are also defined.
QUALITY CONTROL AND QUALITY
ASSURANCE
Quality control (QC) and quality assurance (QA) for
radiotherapy in multicenter clinical trials are vital to evaluate
new investigational treatments. In contrast to the United
States, where a QC/QA program was developed in the late
1960s, it was not developed in the 20th century in Japan. In
2001, we performed a retrospective final review using a
JCOG trial for the first time,10,11 and it revealed that protocol
compliance was very poor, with a protocol violation rate of
60%. After these results, we developed the Radiotherapy
Quality Assurance Center (RTQAC) in the JCOG and
started a comprehensive QC/QA program, including indi-
vidual case reviews (initial and final reviews). The first
trial with a QC/QA program was opened for accrual in
2002. Protocol violation has been decreasing yearly, and it
is now less than 5%.
In the JCOG 0403 study, we asked the National Cancer
Institute and the Advanced Technology Consortium (ATC) to
support this trial in developing a QC/QA program. The digital
data of each case from radiotherapy planning systems are
submitted to the Image Guided Therapy QA Center (ITC) at
Washington University in St. Louis, and the final review is
being performed using the Remote Review Tool provided by
the ITC.
In 2004, we also developed a non-profit organization,
the Radiotherapy Support Center (RSC) to support QC/QA
activities in clinical trials. The RSC, instead of the RTQAC,
is now charged with radiotherapy QC/QA in JCOG trials.
CREDENTIAL PROCESS
Participating institutions in the JCOG 0403 study must
pass through the following requirements: 1) a survey of
institutional personnel, equipment, and treatment techniques;
2) dry run; and 3) phantom dosimetry test. An institutional
survey includes immobilization/localization precision. They
are required to present a document that shows the setup
reproducibility for their choice of immobilization and/or
localization equipment.
A dry run must be performed to reduce inter-institu-
tional variations of treatment planning in compliance with the
protocol and to check the institutional capability of digital
data submission to the ATC. The results of the dry run
performed before the JCOG 0403 study will be reported
elsewhere. The overall coefficient of variation of the target
volumes was approximately 17%, and the inter-institutional
variations in target delineation were acceptable.
Phantom dosimetry test was also performed before
starting the JCOG 0403 study to evaluate the accuracy of
dosimetry in participating institutions to minimize inter-insti-
tutional variations. A lung phantom for SBRT was developed
and used for this purpose. The absolute doses at the center of
a simulated spherical tumor with a diameter of 3 cm in the
lung were measured and compared with the calculated doses
on-site by the responsible physicist.12 The use of heteroge-
neity correction and different calculation algorithms both
significantly influenced the accuracy of the absolute dose.
The differences between the calculated doses with heteroge-
neity correction and measured doses were 4% for the Clark-
son integration algorithm and 1% for the convolution-super-
position algorithm. However, the Clarkson integration
algorithm was selected for the JCOG 0403 study because the
convolution-superposition algorithm was not available in
some participating institutions at the beginning of this study.
CURRENT STATUS AND FUTURE DIRECTIONS
As of January 12, 2007, 111 patients were enrolled in
this study. The accrual of operative patients has been com-
pleted, and that of inoperable patients will be completed in
2008. The final results for operable patients will be avail-
able in 3 years. At that time, we will be able to decide
whether a randomized trial comparing SBRT to surgery is
warranted or whether SBRT should be regarded as an
alternative option for patients who refuse standard surgery.
We also expect that CT criteria will be established to define
local control by analyzing the serial CT data sets mandated in
this study, because the response evaluation criteria in solid
tumors (RECIST) are difficult to apply to see whether the
tumor is eradicated because of secondary changes such as
radiation fibrosis.
Another concern is the optimal dose schedule for this
patient population. We selected 48 Gy in four fractions over
4 to 8 days based on retrospective data using BED formula;
however, it has not been validated to be used in hypofrac-
tionated SBRT with a larger dose per fraction. Without a
dose-finding phase I study, it is also hypothetical that 48 Gy
in four fractions is enough to eradicate the tumor.
In the United States, prospective phase I and phase II
studies have been performed at Indiana University.13,14 Based
on the results, they selected 60 Gy in three fractions over 1.5
to 2 weeks in the following RTOG trial, a phase II trial of
SBRT in patients with medically inoperable stage I/II
NSCLC (RTOG 0236). Not only is the dose schedule differ-
ent from the Japanese schedule, but the target delineation,
margins around the PTV, dose prescription (60% to 90%
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isodose line vs. isocenter), and use of heterogeneity correc-
tion (uncorrected vs. corrected) are also different. These
differences make it difficult to compare the results between
these studies. Recently, the RTOG and JCOG have both
decided to use an up-to-date and more accurate convolution-
superposition algorithm with heterogeneity correction in the
coming studies. The JCOG is now developing a dose-esca-
lating phase I study for T2N0M0 NSCLC, and the RTOG is
also developing a phase II study for operable patients with
stage I NSCLC. We hope that these studies will define the
optimal dose schedule and lead to standardization of the
SBRT technique. Furthermore, international collaboration
will be critical to establish the role of SBRT in the treatment
of lung cancer.
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